Recent Coverage

 

April 10, 2017

Future Tech Podcast
RepliCel – Stem Cell Therapies Using Your Own Cells
To listen to Podcast and View Transcript on Future Tech Podcast, click here Read full article

April 10, 2017

Cantech Letter
RepliCel Life Sciences gets price target raise at Echelon Wealth Partners
To read the full article as it appears on Cantech Letters by Nick Waddell, click here. (3/30/17) Read full article

April 7, 2017

Clinical Trials
Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis (ReaCT)
To read the full study as it appears on ClinicalTrials.gov, click here.  Source: Clinical Trials. gov (4/7/17) Read full article

February 6, 2017

The Financial Post
Podcast: Replicel Life Sciences CEO Lee Buckler on global expansion
To listen to Podcast and View Transcript on Financial Post click here   Read full article

February 1, 2017

The Life Sciences Report
Companies Flocking to Japan for Biotech Deals
To read the full article as it appears on The Life Sciences Report, click here. Source: Colin Lee Novick of The Life Sciences Report  (2/1/17) Read full article

January 28, 2017

ESPN with Bill Daughtry
Listen: http://www.espn.com/espnradio/newyork/play?id=18570324 (at the 1:38 mark) Read full article

January 24, 2017

Zacks Small Cap Research
RepliCel (RP.V) Should Benefit from Renewed Investor Focus, Sweeping Legislation on Cell Therapy
View Article on Zacks Small Cap Research click here Read full article

January 20, 2017

The Huffington Post
Will 2017 be the year of Cell Therapies?
To read the full article as it appears on The Huffington Post, click here. (1/20/17) While 2016 may not go down as a lot... Read full article

January 18, 2017

Investing News
Emerging Biotech Companies at Cantech 2017
ProMIS Neurosciences, RepliCel Life Sciences, and Critical Outcome Technologies take the stage View Article by Pia Rivera on Investing News click here (1/18/2017) Read full article

January 16, 2017

Advisor Access
RepliCel – Using Cells for Healing
View featured company Article on Advisor Access click here Read full article